Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2016
Event: Entry into a Material Definitive Agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial performance. Key transaction metrics include:
- Offering Price: $3.20 per share.
- Firm Commitment: 2,687,500 shares sold to underwriters.
- Registered Direct Offering: 312,500 shares sold to Cedars-Sinai Medical Center.
- Over-Allotment Option: Underwriters granted an option to purchase up to 403,125 additional shares exercisable until October 16, 2016.
- Expected Net Proceeds (Base): Approximately $8.7 million (excluding over-allotment).
- Expected Net Proceeds (Full Over-Allotment): Approximately $9.9 million.
- Expected Closing Date: On or about September 21, 2016.
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt figures. Investors should refer to the Company's Form 10-Q for the quarter ended June 30, 2016, for operational financial data.
Material Changes and Agreements
The primary material change is the execution of two agreements on September 16, 2016:
- Underwriting Agreement: Entered with Roth Capital Partners, LLC and National Securities Corporation for the public offering.
- Subscription Agreement: Entered with Cedars-Sinai Medical Center for the registered direct offering.
Additionally, the Company's directors, executive officers, and certain principal stockholders have entered into "lock-up" agreements prohibiting the sale or transfer of securities until December 15, 2016, subject to limited exceptions.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company expects to close the offering on or about September 21, 2016, subject to customary closing conditions. Proceeds are intended to fund the Company's operations and strategic initiatives, though specific allocation details are not provided in this text.
Risks and Contingencies:
- Closing Risk: The transaction is subject to satisfaction of customary closing conditions; failure to satisfy these could delay or prevent the closing.
- Market Conditions: Actual results may differ from expectations due to market conditions and other uncertainties.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the anticipated closing and proceeds, which are based on information available as of September 16, 2016, and the Company assumes no obligation to update them.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received upon the completion of the offering.
- Confirm whether the underwriters exercised the over-allotment option for the additional 403,125 shares.
- Review the Company's most recent Form 10-Q (filed August 15, 2016) for current cash position and burn rate to assess the impact of the new capital.
- Monitor compliance with the lock-up agreement expiration on December 15, 2016, for potential selling pressure from insiders.